- Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial2019 | Publication without faculty affiliation
- The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil2023 | Publication without faculty affiliation